Education
About Us
Working with TipRanks
Follow Us
Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
GLMD Stock Chart & Stats
$1.34
-$0.05(-1.56%)
At close: 4:00 PM EST
$1.34
-$0.05(-1.56%)
Day’s Range― - ―
52-Week Range$1.15 - $4.81
Previous CloseN/A
Volume19.24K
Average Volume (3M)84.25K
Market Cap
$7.78M
Enterprise Value-$13.39M
Total Cash (Recent Filing)$20.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding5,479,231
10 Day Avg. Volume86,643
30 Day Avg. Volume84,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.50
Enterprise Value/Market Cap-1.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Partnerships And CollaborationsGalmed has partnered with Virginia Commonwealth University to evaluate Aramchol’s potential in oncology indications.
Product DevelopmentGalmed signed a term sheet with Entomus to develop a sublingual GLP-1 compound, potentially treating obesity, which led to a significant increase in shares.
Bears Say
Clinical TrialsThe company halted the Phase 3 trial for Aramchol meglumine due to financial and enrollment issues.
Strategic UncertaintyGalmed's strategic positioning and path forward remains unclear.
Galmed Pharmaceuticals News
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $1.15 and its highest was $4.81 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is $7.78M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is May 20, 2026 which is in 209 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Galmed Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.83 by $0.2.
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 5,479,231 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Galmed Pharmaceuticals reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.83. Following the earnings report the stock price went down -3.55%.
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in GLMD
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutic solutions to address liver diseases. The company's primary product candidate, Aramchol, is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Galmed Pharmaceuticals operates within the biotechnology and pharmaceutical sectors, with its research and development efforts aimed at addressing unmet medical needs in the area of liver health.
Technical Analysis
Matinas BioPharma
―
Hepion Pharmaceuticals
―
Quoin Pharmaceuticals
―
InMed Pharmaceuticals
―
Galecto
―
Ownership Overview
6.20%
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---